Stock Research for TROV

TROV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TROV Stock Chart & Research Data

The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TROV Due diligence Resources & Stock Charts

The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TROV Detailed Price Forecast - CNN Money CNN View TROV Detailed Summary - Google Finance
Yahoo View TROV Detailed Summary - Yahoo! Finance Zacks View TROV Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View TROV Trends & Analysis - Trade-Ideas Barrons View TROV Major Holders - Barrons
NASDAQ View TROV Call Transcripts - NASDAQ Seeking View TROV Breaking News & Analysis - Seeking Alpha
Spotlight View TROV Annual Report - CompanySpotlight.com OTC Report View TROV OTC Short Report - OTCShortReport.com
TradeKing View TROV Fundamentals - TradeKing Charts View TROV SEC Filings - Bar Chart
WSJ View Historical Prices for TROV - The WSJ Morningstar View Performance/Total Return for TROV - Morningstar
MarketWatch View the Analyst Estimates for TROV - MarketWatch CNBC View the Earnings History for TROV - CNBC
StockMarketWatch View the TROV Earnings - StockMarketWatch MacroAxis View TROV Buy or Sell Recommendations - MacroAxis
Bullish View the TROV Bullish Patterns - American Bulls Short Pains View TROV Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View TROV Stock Mentions - StockTwits PennyStocks View TROV Stock Mentions - PennyStockTweets
Twitter View TROV Stock Mentions - Twitter Invest Hub View TROV Investment Forum News - Investor Hub
Yahoo View TROV Stock Mentions - Yahoo! Message Board Seeking Alpha View TROV Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for TROV - SECform4.com Insider Cow View Insider Transactions for TROV - Insider Cow
CNBC View TROV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TROV - OTC Markets
Yahoo View Insider Transactions for TROV - Yahoo! Finance NASDAQ View Institutional Holdings for TROV - NASDAQ


Stock Charts

FinViz View TROV Stock Insight & Charts - FinViz.com StockCharts View TROV Investment Charts - StockCharts.com
BarChart View TROV Stock Overview & Charts - BarChart Trading View View TROV User Generated Charts - Trading View


Latest Financial News for TROV

Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine
Posted on Tuesday April 17, 2018

Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b /2 Clinical Trial of PCM-075. Update on clinical trial recruitment. SAN DIEGO , April 17, 2018 /PRNewswire/ ...


Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
Posted on Monday April 16, 2018

Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model SAN DIEGO , April 16, 2018 /PRNewswire/ ...


Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018
Posted on Thursday April 12, 2018

SAN DIEGO , April 12, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor ...


Trovagene to Present at the 26th Annual Wall Street Investor Conference
Posted on Tuesday March 20, 2018

SAN DIEGO, March 20, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, developing targeted therapeutics to treat hematologic and solid tumor cancers, announced today that it will be presenting at The Wall Street Investor Forum 26th Annual Investor Conference in New York City at The University Club of NYC at 2:05 PM EDT / 11:05 AM PDT on Thursday, March 22, 2018. Bill Welch, Chief Executive Officer of Trovagene, will be presenting, as well as meeting with investors. Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit https://www.trovagene.com.


Revenue Approximations Analysis: TrovaGene, Inc. (TROV), New York Mortgage ...
StockNewsJournal - Apr 25, 2018
Investors who are keeping close eye on the stock of TrovaGene, Inc. (NASDAQ:TROV) established that the company was able to keep return on investment at -111.96 in the trailing twelve month while Reuters data showed that industry's average stands at 14 ...

Trovagene Announces Presentations at the American Association for Cancer ...
PR Newswire (press release) - Apr 12, 2018
SAN DIEGO, April 12, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced that three posters ...
Suggestions before Buy or Sell action: TrovaGene, Inc. (TROV) - Nasdaq Express

TrovaGene Inc's (NASDAQ:TROV) Poor Growth Outlook Brings Concerns
Simply Wall St - Apr 23, 2018
TrovaGene Inc (NASDAQ:TROV) is a company I've been following for a while, and one that I believe the market is over-hyped about.
Trovagene Inc (TROV) Trending Activity with Technical Depiction - Emn News
Analysts See $-0.08 EPS for TrovaGene, Inc. (TROV) - Frisco Fastball

An End-of-Day Technical Review: Regions Financial Corporation (RF), TrovaGene ...
Post Analyst - Apr 24, 2018
Regions Financial Corporation (NYSE:RF) last session's volume of 15.18 million shares was higher than its average volume of 11.85 million shares.

Enter a stock symbol to view the stock details.